Vasko Kramer

Head of R&D

Positronmed Ltd. (Prestaciones Medicas AyC Ltda.)

Santiago, Chile

Líneas de Investigación

Investigación y desarrollo de radiofármacos para la obtención de imágenes PET y el tratamiento en oncología. Investigación traslacional de radiofármacos y coordinación de estudios clínicos en estrecha colaboración con especialidades asociadas.


  •  Química radiofarmaceutica, Johannes Gutenberg-Universidad Mainz. Alemania, 2012
  •  Quimica, Johannes Gutenberg-Universidad Mainz. Chile, 2008

Experiencia Académica

  •   Asistente cientifico Full Time



    Mainz, Alemania

    2008 - 2012

Experiencia Profesional

  •   Asesor I+D Part Time

    Positronmed Ltda

    Santiago, Chile

    2013 - At present

  •   Gerente I+D Part Time

    Positronpharma SA

    Santiago, Chile

    2012 - At present

  •   Gerente General Other

    Acrux Radiopharma Consulting SpA

    Santiago, Chile

    2012 - At present

Difusión y Transferencia

Co-Organizer of the Theranostic World Congress (TWC) 2022 in Wiesbaden:


Article (19)

Al[F-18]F-NOTA-Octreotide Is Comparable to [Ga-68]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Synthesis and in vivo evaluation of [C-11]tucatinib for HER2-targeted PET imaging
Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein
Whole-body biodistribution and radiation dosimetry of [F-18]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders
A theranostic approach of [68Ga] Ga-DOTA. SA. FAPi PET/CT-guided [177Lu] Lu-DOTA. SA. FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted …
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu] Lu-PSMA-ALB-56 in patients with mCRPC
Biodistribution, pharmacokinetics, dosimetry of [68Ga] Ga-DOTA. SA. FAPi, and the head-to-head comparison with [18F] F-FDG PET/CT in patients with various cancers
Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2
Characterization of the serotonin 2A receptor selective PET tracer (R)-[F-18]MH.MZ in the human brain
Evaluation of [F-18]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies
Detection Efficacy of F-18-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
Pharmacokinetic evaluation of [F-18]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain
Image-Guided Development of Heterocyclic Sulfoxides as Ligands for Tau Neurofibrillary Tangles: From First-in-Man to Second-Generation Ligands
F-18-Labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging
Structural Combination of Established 5-HT2A Receptor Ligands: New Aspects of the Binding Mode
Synthesis and in vitro affinities of various MDL 100907 derivatives as potential F-18-radioligands for 5-HT2A receptor imaging with PET

Abstract (3)

[18F] PR04.MZ for Dopamine Transporter Quantification in Low Density Regions - Complete Evaluation and Dosimetry in Healthy Volunteers
Quantification of 5HT2A-Receptors in the Human Brain with [18F]MHMZ
[18F]PR04. MZ for Quantification of Striatal and Extrastriatal Dopamine Transporters in Patients with Idiopathic Parkinson's Disease

EditorialMaterial (1)

Imaging Nigrostriatal Dopaminergic Deficit in Holmes Tremor with F-18-PR04.MZ-PET/CT

Proyecto (5)

A new production method for a radioisotope used for non-invasive diagnose and monitoring of prostate cancer
Manifestaciones prodrómicas de la Enfermedad de Parkinson en un grupo de alto riesgo=> personas con síndrome de microdeleción 22q11.2
Radiopharmaceuticals to visualize neurofibrillary tangles in vivo
Desarrollo, Implementación y Validación Clínica de Radiofármacos para la Detección Temprana y Diferencial de la Enfermedad de Parkinson mediante Neuroimágenes PET/CT para el Mercado Nacional e Internacional
Extrastriatal Dopaminergic Function in REM Sleep Behavioral Disorder
Vasko Kramer

Head of R&D

Investigación y Desarrollo

Positronmed Ltd. (Prestaciones Medicas AyC Ltda.)

Santiago, Chile






Pedro Chana Cuevas

Profesor Titular

Facultad de Ciencias Medicas

Universidad de Santiago

Santiago, Chile